

# Routine Accurate Mass Measurement for the Identification of Impurities in Quetiapine Fumarate API Using the SmartMS-Enabled ACQUITY RDa Detector

Tirupateswara Rao. B, Dilshad Pullancheri, Bheeshmacharyulu S, Dr. Padmakar Wagh

Waters Corporation

### Abstract

This application note demonstrates a simplified workflow for routine accurate mass measurement for the identification of Quetiapine and its related impurities with the ACQUITY RDa Detector. The full scan with fragmentation function provides simultaneous acquisition of both low and high energy data, maximizing the information gathered from a single injection. The UNIFI Application Workflow streamlines the fragment analysis and structural elucidation process and provides greater confidence in the end results. This workflow-based approach delivers rapid comprehensive results for identification and confirmation of impurities in Quetiapine fumarate API (active pharmaceutical ingredient). The API and its related impurities were identified and reported using the UNIFI application within the waters\_connect Software platform. The full scan with fragmentation function of ACQUITY RDa Detector generated fragment ion information. By ramping the fragmentation cone voltage additional structural information was generated.

Knowledge of the impurity profile of a drug is vital as the chemical degradation of its active component often results in a loss of potency, affecting its efficacy and safety; therefore, it is important to study its stability using an appropriate analytical tool such as high-resolution mass spectrometry (HRMS). The ACQUITY RDa Detector, with its automatic set up and calibration, allows accurate mass measurements to be obtained by scientists with a diverse range of analytical expertise. Thus, providing access to HRMS for non-expert users and empowering

Routine Accurate Mass Measurement for the Identification of Impurities in Quetiapine Fumarate API Using the SmartMS-Enabled ACQUITY RDa Detector

scientists with a far greater depth of analytical information.



Figure 1.

2

### ACQUITY RDa Detector.

### **Benefits**

- · Routine accurate mass measurements for the impurity profiling
- · Compact benchtop system with SmartMS Technology
- · Intuitive system health checks and dedicated end-to-end workflows
- · Compliant ready system with data integrity

### Introduction

Quetiapine fumarate (QUE) is considered as an atypical or second-generation antipsychotic agent. It is also used for the treatment of depressive episodes associated with bipolar disorder (McEvoy, 2016). QUE was initially developed for the treatment of psychiatric disorders, but due to the added effect of causing sedation, it is now widely used off-label as a treatment for insomnia (Anderson and Vande, 2014) QUE has a chemical structure susceptible to degradation (Figure 2); so, it is important to assess the presence of impurities by suitable analytical techniques such as HRMS. Analytical determination of impurities is often time-constraining and resource-consuming. Analysts require a range of mass spectrometry capabilities as well as sophisticated software to facilitate data processing of these complex impurity data sets. This work demonstrates a systematic workflow that is capable of highly specific and sensitive detection of impurities that are present in quetiapine fumarate (API) drug substance. This workflow-based approach improves the confidence in impurity identification and rapid structural elucidation facilitated by intelligent and user-friendly software. The software performs fragment analysis, correlating the precursor ion information of the low-energy data to that of the fragment ion information of the high-energy data. HPLC with UV detection is a widely used analytical technique for the impurity profiling. Due to its limited sensitivity and specificity, however, HRMS is often required to overcome these issues.



Figure 2. Quetiapine.

The ACQUITY RDa Detector with SmartMS capabilities enables scientists, who are non-expert users of HRMS, to access accurate mass measurements with in-depth analytical information. Additionally, the waters\_connect Software platform acquires, processes and reports results in a complaint-ready framework using a dedicated end-to-end workflow. The full scan with fragmentation function, simultaneously acquires both low and high energy spectra, generating fragment ion information for increased confidence in compound identification.

### Experimental

The ACQUITY RDa Detector, coupled to an ACQUITY UPLC I-Class PLUS System, was used for the impurity analysis of Quetiapine fumarate using XBridge  $C_{18}$  (4.6 mm x 150 mm, 3.5 µm) as the stationary phase. The ACQUITY RDa Detector is a compact, benchtop Tof mass spectrometer that has a mass resolution of >10,000 FWHM for routine accurate mass measurements. The system acquired both full scan data and full scan with fragmentation data (data independent acquisition). The UNIFI Application utilizes accurate mass, retention time, and compound fragmentation data to search a customizable application specific library to identify the compound. Figure 1 shows the ACQUITY RDa Detector.

### Sample Description

5 mg/mL sample solution of Quetiapine fumarate was prepared using solution A (Buffer: ACN-3:1) as a diluent.

### LC Conditions

#### LC system:

#### ACQUITY UPLC I-Class PLUS

Detection:	TUV@250 nm
Vials:	Total Recovery Vials
Column(s):	XBridge C <sub>18</sub> , 4.6 x 150 mm, 3.5 μm
Column temperature:	45 °C
Sample temperature:	10 °C
Injection volume:	20 µL
Flow rate:	1.5 mL/min
Buffer:	6.2 grams of Ammonium acetate in 2 L Water and
	adjust the pH 9.2 with Ammonium hydroxide
Mobile phase A:	1500 mL of Buffer + 500 mL of Acetonitrile
Mobile phase B:	Acetonitrile

### Gradient Table

Time (min)	Flow (mL/min)	%A	%В	Curve	
Initial	1.5	100	0	6	
25.00	1.5	100	0	6	
60.00	1.5	29.3	70.7	6	
60.01	1.5	74	26	6	
70.00	1.5	60	40	6	

### **MS** Conditions

MS system:

ACQUITY RDa Detector

Ionization mode:	Full scan with fragmentation (pseudo - $\ensuremath{MS^E}$
	acquisition)
Acquisition range:	50-2000 <i>m/z</i>
Capillany voltage	15 10/
Capillary Voltage.	1.5 KV
Fragmentation cone voltage:	50-90 V
Cone voltage:	30 V
Polarity:	Positive ion mode
Scan rate:	5 Hz
	-
Desolvation temperature:	550 °C

### Data Management

Informatics:

waters\_connect v1.9.12

# **Results and Discussion**

The ACQUITY RDa Detector utilizes the accurate mass workflows for exact mass measurement required for identification and smart decision making. This work demonstrates the UNIFI Software application workflow for impurity analysis, which can also be extended to degradation studies, as shown in Figure 3.



Figure 3. UNIFI Application workflow for analysis.

Figure 4 shows a comparison between UV chromatogram and MS BPI chromatogram in ESI positive ion mode.



Figure 4. UV chromatogram at 250 nm vs MS BPI (base peak intensity) chromatogram in ESI positive ion mode of quetiapine fumarate formulation sample.

Quetiapine fumarate API sample (1 mg/mL) was acquired by full scan with fragmentation function of the ACQUITY RDa Detector, where the low energy channel contains the parent ion information and the high energy channel contains the fragment ion information (Figure 5).





To get an elemental composition for every peak found in a chromatogram, the analyst would typically have to combine MS scans and perform background subtraction for each peak of interest and then generate reports for individual elemental composition. The UNIFI Software populates all impurity peaks integrated in the Tof-MS ES+ chromatographic trace with associated elemental compositions, mass accuracy, and isotope pattern scoring using i-FIT, and displays the results in a single window. Evaluation of the unknown impurity peaks by exact mass and elemental composition using UNIFI Software indicates that the mass accuracy of the API Quetiapine is sub 2 ppm. Nine known impurities were observed with an average mass accuracy of 2 ppm. Software aligns the high and low collision energy data that were simultaneously collected during the pseudo MS<sup>E</sup> acquisition. The resulting information was displayed in a collective window where the precursor and fragment ions were evaluated spectrally and presented chromatographically.

Here in this application note we have demonstrated two different approaches; one using "Discovery Tool" and the other with "Transformations Tool" to identify an unknown impurity, as shown in Figure 6.



Figure 6. Discovery Tool approach and Transformations Tool approach for the identification of

unknown impurity.

The integrated Discovery Tool allows the user to interrogate unidentified peaks and quickly perform a structural database ChemSpider search for putative identifications of the unknown compound.

By using Discovery Tool, we can identify the Quetiapine peak at RT of 32.9 minutes as shown in figure 7.



Figure 7. Quetiapine peak at 32.70 minutes.

The Discovery Tool takes the accurate mass measured at 32.9 minutes, proposes the elemental formulae and searches in the selected ChemSpider libraries for the possible compounds. In this case, six possible database

matches were found. The Discovery Tool also performs an *in-silico* fragmentation to yield theoretical fragment ions for the database match and compares this spectrum with the acquired fragment ion spectrum. The first candidate found is Quetiapine which matches the spectral composition of the unknown peak as shown in Figure 8.

Workflow 💽 Spectra Spectra	Discovery •						
Summary Ben name 1774-0212 Sample Soldio Oxanel name Low energy: Time 3109 © 2 0. Reich, Duminer Ben devision:	meter preferences 👻 🚔						
Accurate Mass Screeni 384.17280 6.8540 Discovey Demental Compusiton Chemopole Fagement Match							
o laterited Compon 6el							
Ukinuan Compania Ukinuan Sentitar Sentitar							
Buddation Tools      By 4e9     Action Management Computational Toxicology Resource     Addam Matheman							
Advanced Constitution of Const							
Ban X Cana							
422.12832 Results (5 found)							
56.6400 278.09132 38.33101 42.31124 597.16664 🖉 Component Name n/z Beneratia Composition 4-317 Confidence (%) Common Name	<b>A</b>						
0 100 200 300 400 500 0 1 1 Consider Mars B417807152/4 184778 C14254005 9980 Quespine							
Rem description:         27ed         Conduct Multi Sk1720071524         18k172         C10550035         798         2/js450005(press)piceting/conductive/sk172001546	-c]pyridin-2-y()-2-(4-meth						
384.17461							
24-							
Information							
Curtager Curtag							
1 Queliapire 2000 11 Queliapire	Ĩ						
2 Sempert 22 Sem							
233.0781 342.1542 406.15422 342.1543 406.15422 342.1543 406.15422 342.1543 406.15422 342.1543 406.15422 342.1543 406.15422 342.1543 406.15422 342.1543 406.1542 342.1542 406.1542 342.1542 406.1542 342.1542 406.1542 342.1542 406.1542 342.1542 406.1	362:157 406:155						
6 100 200 300 400 500 600 5 2.2 4 Ebarrad L/L (L Atbaugier 1 + 1 + 2 - 5 - 5 - 2 - 5 - 2 - 5 - 5 - 2 - 5 - 5	350 400						

Figure 8. Identification of Quetiapine by using Discovery Tool with the help of ChemSpider library. For impurity profiling, the Discovery Tool can be used for API identification and a scientific library created with the identified compounds for routine analysis. Scientific library for Quetiapine and its related impurities has been created by using the available literature as shown in Figure 9.

Search results (22 items found)								
	Name 1 🔺	Library name	Formula	Monoisotopic mass (g/mol)				
1	Impurity A	Quetiapine	C23H27N3O3S	425.1773				
2	Impurity B	Quetiapine	C17H17N3S	295.1143				
3	Impurity C	Quetiapine	C40H42N6O3S2	718.2760				
4	Impurity D	Quetiapine	C30H24N4S2	504.1442				
5	Impurity E	Quetiapine	C40H44N6O2S2	704.2967				
6	Impurity F	Quetiapine	C21H27N3O3S	401.1773				
7	Impurity G	Quetiapine	C13H9NOS	227.0405				
8	Impurity H	Quetiapine	C21H25N3O3S	399.1617				
9	Impurity I	Quetiapine	C19H21N3OS	339.1405				
10	Impurity J	Quetiapine	C25H33N3O4S	471.2192				
11	Impurity K	Quetiapine	C23H29N3O4S	443.1879				
12	Impurity L	Quetiapine	C21H24CIN3O2S	417.1278				
13	Impurity N	Quetiapine	C29H41N5O3S	539.2930				
14	Impurity O	Quetiapine	C40H39N3O2S	625.2763				
15	Impurity P	Quetiapine	C19H21N3S	323.1456				
16	Impurity Q	Quetiapine	C25H34IN3O4S	599.1315				
17	Impurity T	Quetiapine	C17H16N2OS	296.0983				
18	Impurity U	Quetiapine	C13H10N2S	226.0565				
19	Impurity V	Quetiapine	C21H25N3O2	351.1947				
20	Impurity W	Quetiapine	C34H32N4O2S2	592.1967				
21	Quetiapine	Quetiapine	C21H25N3O2S	383.1667				
22	Quetiapine fumarate	Quetiapine	C46H54N6O8S2	882.3445				

Figure 9. Scientific library of Quetiapine and its related impurities.

By using Discovery Tool, we can identify the Quetiapine related impurity peak at RT of 30.45 minutes as shown in Figure 10.



Figure 10. Quetiapine related impurity peak at 30.45 minutes.

The Discovery Tool takes the accurate mass measured at 30.45 minutes, proposes the elemental formulae and searches in the selected Scientific library for the possible compounds. The Discovery Tool also performs an *insilico* fragmentation to yield theoretical fragment ions for the database match and compares this spectrum with the acquired fragment ion spectrum. The candidate found is Impurity-I which matches the spectral composition of the unknown peak as shown in Figure 11.



Figure 11. Identification of Quetiapine related impurity by using Discovery Tool with the help of

Scientific library.

Figure 12 demonstrates the identification of Quetiapine and its related impurities by using the scientific library.

dentification status 4 dentified dentified tentified tentified tentified tentified tentified dentified tentified ten	Polserved m/z         Ma           386.1733         340.1477           340.1477         400.1665           426.1840         296,1211           418.1342         540.2988           9.93.2024         418.1343           505.1503         7000000000000000000000000000000000000	ss error (mDa) Mass -0.7 -0.1 -0.5 -0.6 -0.5 -0.8 -1.5 -1.5 -1.5 -1.2	error (ppm) Obse -1.8 -0.4 -1.2 -1.5 -2.0 -2.8 -2.8 -1.8 -2.3	erved RT (min) 33.04 30.45 8.24 39.50 25.33 38.93 33.31 53.89 37.10 55.02 25.02	Add         Add           31378205         +H           660180         +H           409264         +H           64516         +H           66923         +H           26924         +H           26924         +H           26924         +H           21509         +H           10254         +H           10254         +H	lects +Na, +К, +Ls +К +Na, +К	(+4) ا ا ا ا ا ا ا ا ا ا ا ا ا
dentiled dentiled dentiled dentiled dentiled dentiled dentiled dentiled dentiled dentiled minole Solution_1mg/ p (+H) : (5.0 PPM 384	384,1738 340,1477 400,1665 426,1840 426,1840 540,2968 593,2024 418,1342 505,1503	-07 -01 -05 -08 -15 -15 -15 -15 -12	-18 -0.4 -1.2 -1.5 -1.7 -2.0 -2.8 -2.5 -1.8 -2.3	33.04 30.45 8.24 39.50 25.33 38.93 33.31 53.89 37.10 55.02	31378205 +H 690180 +H 409264 +H 84516 +H 67933 +H 48652 +H 26924 +H 21509 +H 13713 +H 10254 +H	*Nia, +K +K +Nia, +K	- بن المحمد المحمد المحمد المحمد المحمد المحم المحمد المحمد
dentified dentified dentified dentified dentified dentified dentified dentified dentified dentified minole Solution_1mg/ r (+11):(5.0 PPM) 384	340.1477 400.1685 426.1840 296.1211 418.1342 540.2988 593.2024 418.1343 505.1503	-0.1 -0.5 -0.6 -0.5 -0.8 -1.5 -1.5 -1.5 -1.2	-0.4 -1.2 -1.5 -1.7 -2.0 -2.8 -2.5 -1.8 -2.3	30.45 8.24 39.50 25.33 38.93 33.31 53.89 37.10 55.02	690180 +H 409264 +H 84516 +H 67933 +H 26924 +H 21509 +H 13713 +H 10254 +H 10254 +H	+K +Ns,+K	در المراجع الم المراجع المراجع
dentilied dentilied dentilied dentilied dentilied dentilied mple Solution_1mg/ p (+H): (5.0 PPA) 384	400.1685 426.1840 296.1211 418.1342 540.2988 593.2024 418.1343 505.1503	-0.5 -0.6 -0.5 -0.8 -1.5 -1.5 -0.8 -1.2	-12 -15 -17 -20 -28 -25 -18 -23	824 3950 2533 3893 3331 5389 37.10 55.02	409264 +H 84516 +H 67933 +H 48652 +H 26924 +H 21509 +H 13713 +H 10254 +H	+K +Na, +K	د معند معند معند معند معند معند معند معن
dentified dentified dentified dentified dentified dentified mple Solution_1mg/ s (+H) : (5.0 PPM) 384	426.1840 296.1211 418.1342 540.2988 593.2024 418.1343 505.1503	-0.8 -0.8 -1.5 -1.5 -0.8 -1.2	-15 -17 -20 -28 -25 -18 -23	3950 2533 3893 3331 5389 37.10 55.02	84516 +H 67933 +H 48652 +H 26924 +H 21509 +H 13713 +H 10254 +H 10254 +H	+Na, +K	د المحمد المحمد
dentified dentified dentified dentified dentified mple Solution_1mg/ = (+H) : (5.0 PPM) 384	296.1211 418.1342 540.2988 593.2024 418.1343 505.1503	-0.5 -0.8 -1.5 -1.5 -0.8 -1.2	-1.7 -2.0 -2.8 -2.5 -1.8 -2.3	25.33 38.93 33.31 53.89 37.10 55.02	57933 +H 48552 +H 26924 +H 21509 +H 13713 +H 10254 +H	+ Na, +K	Spenta • 33 11 29 • 4 <sup>(1)</sup> □
dentified dentified dentified dentified mple Solution_1mg/ p (+H) : (5.0 PPM) 394	418.1342 540.2988 593.2024 418.1343 505.1503	-0.8 -1.5 -1.5 -0.8 -1.2	-20 -2.8 -2.5 -1.8 -2.3	38.93 33.31 53.89 37.10 55.02	48552 +H 26924 +H 21509 +H 13713 +H 10254 +H	+Na, +K	Spenta • III III → ⊕ IIII
dentified dentified dentified mple Solution_1mg/ s (+H) : (5.0 PPM) 384	540.2988 593.2024 418.1343 505.1503	-1.5 -1.5 -0.8 -1.2	-28 -25 -1.8 -2.3	33.31 53.89 37.10 55.02	26924 +H 21509 +H 13713 +H 10254 +H	+Na, +K	د کار الکوستین کار الکار کار کار کار کار کار کار کار کار کار
klentified klentified mple Solution_1mg/ = 1+H1 : (5.0 PPM) 38-	593.2024 418.1343 505.1503	-1.5 -0.8 -1.2	-25 -1.8 -2.3	53.89 37.10 55.02	21509 +H 13713 +H 10254 +H		Spectra • 33 11 29 • 4 💷
identified imple Solution_1mg/ = 1+H1 : (5.0 PPM) 384	418.1343 505.1503	-0.8 -1.2	-1.8 -2.3	37.10 55.02	13713 +H 10254 +H		Spectra • 🔤 🗃 🎝 • 🔶 💿 🖻
identified imple Solution_1mg/ > 1+H1 : (5.0 PPM) 384	505.1503	-1.2	-2.3	55.02	10254 +H		Spenze II II P + 4
mple Solution_1mg/	/mL	_		5 %	111 <b>7</b> 3 - 4	GE	Spectro • 🔄 🛄 🗃 • 🔶 🗔
mple Solution_1mg/ [+H] : (5.0 PPM) 384	/mL						
							25397732 27427326 32227796 341.15198 363.654492
						0	item name: 17Feb2021 Samole Solution 1mo/mL Channel name: High energy : Time 33.0416 +/- 0.1929 minutes * ×
10 15	20 25	30 35	40 45	50 55	60 65	70	Nem description:         384.175517268           2.2.0         210.019569 221.10553         253.07905         270.02466         323.13963           156.175         175         200         325         350         375
		10 15 20 25	10 15 20 25 30 36 Retriction time (m	10 15 20 25 30 35 40 45 Retriction time [mr]	10 15 20 25 30 35 40 45 50 55 Reterior time [mm]	10 15 20 25 30 35 40 45 50 55 40 45 Setrion time [mi]	10 15 20 25 30 15 40 45 50 55 60 65 70 Retricto tirre [m]

Figure 12. Identification of Quetiapine and its related impurities by using scientific library.

In the initial stage, UNIFI's Discovery Tool can be used to find the possible identity of the API and impurities. Alternatively, impurities related to API which are potential transformations (oxidations, reductions, dealkylations, etc.) were then successfully identified using the inbuilt transformation tool within the UNIFI application. The suspected impurities are shown within the component summary where all peaks are listed that match the m/z of predicted impurities (Figure 13). The chromatogram and spectral view are also displayed, with the automatic fragment ion assignment in the high energy spectrum annotated with the blue icon (Figure 13). Incorporating the impurity analysis workflow, shown on the left-hand side of Figure 13, is an efficient and effective approach to identifying unknown impurities that are related to API.

w • •	🎳 Tray: 1:8,4 👘 🙀 1	7Feb2021_Sample S	0	Quetiapine	•					Trilters -
lorkflow 📿 -	Component Summary *									🚺 t # 🕲 🕞 🗄
mary	∠ Component name	Identification status Observed R	(min) Obs	erved m/z Adducts	Formula	Mass error (mDa)	Mass error (ppm)	Resp., 1-		
tch Overview	1 Quetispine	Identified	32.74	384.1734 +H	C21H25N3D25	-0.6	-16	31351683		
rity Analysis	2 Quetispine-C2H4O(cleavage)	Identified	30.15	340.1476 +H	C19H21N3O5	-0.2	-0.6	686926		
rity Review	3 Quetapine+D	Identified	7.94	400.1685 +H	C21H2SN3D3S	-0.4	-11	406211		
mparison	4 Quetiapine-O(cleanage)+H2+C2H2O	Identified	40.58	412.2044 +H	C23H29N3D25	-1.0	-2.4	143449		
	5 Quetiapine+C2H2O	Identified	39.20	426.1839 +H	C23H27N3O3S	-0.7	-1.6	84441		
ization	6 Quetiapine-H2	Identified	38.34	382.1574 +H	C21H23N3D2S	-0.9	-2.4	69809		
	7 Quetiapine-C4H8O2(cleavage)	Identified	25.08	296.1211 +H	C17H17N35	-05	-16	67933		
s Samples	8 Quetiapine+H2+C2H2O	Identified	33.34	428.1983 +H	C23H29N3D35	-2.0	-47	47568		
	9 Quetiapine=CH2	Identified	35.97	390.1885 +H	C22H27N3O25	-1.1	-2.9	39451		
rbes	10 Quetapine-H2D	Identified	10.72	366.1618 +H	C21H23N3O5	-1.6	-43	21362		
tated	11 Quetiapine+H2D+SD3	Identified	32.65	482.1391 +H	C21H27N3D652	-23	-4.7	16774		
	12 Quetiapine-C2H4Q2(cleavage)-H2+D2-H2+C2H2O	Identified	5.16	394.1208 +H	C21H19N3D3S	-12	-31	8656		
	13 Quetiapine + O + C2H2O	Identified	45.04	442.1787 +H	C23H27N3D45	-0.9	-1.9	5234		
4	Chromotownee a			F1 05 .4			10.1			
	Rem name: 17Feb2021 Sample Solution 1mo/mL					e × Item	name: 17Feb2021 1	Sample Solution 1mg/mL	Channel name: Low energy : Time	32.7416 +/- 0.1929 minutes
	Charlent came Gardiagnet (14) (0.5 796) BA 1714 663 663 100001 665 265 265	Deticipre 32.0				the state of the s	description 0 150 1 name: 17Feb2021.3 description: 08	75 200 225 ample Soluton_Img/mL	21427332 259 215 310 325 Okaral name High energy Trie	384.17240 7.0245 381.65007 350 375 400 327416 +/- 0.1920 mutes # × 354.17229 2.7248
	0 5 10 15 20	25 30 35 4	0 45	50 55	60 65	70	0 158.11770	210,03673 221,10658 75 200 225	253.07911 279.09471 323.13969 250 275 300 325	352,20104 382,15738 350 375 400

Figure 13. Identification of related impurities of Quetiapine fumarate API by using transformations tool and incorporating the impurity analysis UNIFI workflow.

All related impurities of Quetiapine fumarate were identified using ACQUITY RDa Detector with waters\_connect platform.

### Conclusion

Data collection using the ACQUITY RDa Detector coupled with the ACQUITY UPLC I-Class PLUS System and TUV provided ample sensitivity, and superior mass accuracy to identify many of the impurities in the quetiapine fumarate drug substance. Pseudo MS<sup>E</sup> provided simultaneous acquisition of both high and low energy data, maximizing the information gathered from a single injection. This analytical workflow was followed by a data processing workflow that streamlined the fragment analysis and structural elucidation process and provided greater confidence in the end results.

The identification of quetiapine and its 9 impurities were rapidly confirmed. The combination of the software tools, along with the optimized instrument configurations for impurity analysis and efficient pseudo MS<sup>E</sup> acquisition, provided a systematic workflow approach that can readily be applied to identify and confirm known and unknown peaks in impurity profiling. This workflow-based approach delivers the rapid and systematic set of comprehensive results that are needed to identify and confirm impurities in an API impurity profiling study.

### References

- Anderson, S., and Vande, J. (2014). Quetiapine for Insomnia: A Review of the Literature. *American Journal of Health-System Pharmacy*, 71, 394–402. <u>https://doi.org/10.2146/ajhp130221 < https://doi.org/10.2146/ajhp130221></u>.
- Bharathi, C., Prabahar, K., Prasad, C., Srinivasa, R., Trinadhachary, G., Handa, V., Naidu, A. (2008).
   Identification, Isolation, Synthesis and Characterization of Impurities of Quetiapine Fumarate. *Pharmazie*, 63, 14–19.
- Fisher, D., Handley, S., Flanagan, R., and Taylor, D. (2012). Plasma Concentrations of Quetiapine, Ndesalkylquetiapine, O-desalkylquetiapine, 7- hydroxyquetiapine, and Quetiapine Sulfoxide in Relation to Quetiapine Dose, Formulation, and other factors. *Therapeutic Drug Monitoring*, 34, 415–421. <u>https://doi.org/10.1097/FTD.0b013e3182603f62 < https://doi.org/10.1097/FTD.0b013e3182603f62 > .</u>
- Jones, MD, et al. Identification and Characterization of an Isolated Impurity Fraction: Analysis of an Unknown Degradant Found in Quetiapine Fumarate. Waters Corporation. 2009; <u>720003079EN</u>.
- Impurity Isolation and Scale-up from UPLC: Analysis of an Unknown Degradant Found in Quetiapine Fumarate. Waters Corporation. 2009; <u>720003078EN</u>.

## Featured Products

- ACQUITY UPLC I-Class PLUS System < https://www.waters.com/134613317>
- ACQUITY UPLC Tunable UV Detector <a href="https://www.waters.com/514228>">https://www.waters.com/514228></a>
- <u>UNIFI Scientific Information System <https://www.waters.com/134801648></u>
- waters\_connect <https://www.waters.com/waters/nav.htm?cid=135040165>
- ACQUITY RDa Detector <https://www.waters.com/waters/nav.htm?cid=135077027>

720007354, September 2021

### $\wedge$

© 2021 Waters Corporation. All Rights Reserved.